**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 82803

**Manuscript Type:** REVIEW

**Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus**

Shi YJ *et al*. Adipose tissue in HFpEF with diabetes

Yu-Jiao Shi, Guo-Ju Dong, Ming Guo

**Yu-Jiao Shi, Guo-Ju Dong, Ming Guo,** Department of Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, Beijing 100091, China

**Author contributions:** Shi YJ performed most of the writing and prepared the figures and tables; Dong GJ and Ming G performed data accusation and writing; Dong GJ and Ming G designed the outline and coordinated the writing of the paper.

**Corresponding author: Guo-Ju Dong, MD, PhD, Chief Physician,** Department of Cardiovascular Medicine, Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine, No. 1 Xiyuan Playground, Haidian District, Beijing 100091, China. 13691393589@163.com

**Received:** December 28, 2022

**Revised:** February 10, 2023

**Accepted:** April 24, 2023

**Published online:** June 15, 2023

**Abstract**

Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with various comorbidities, multiple cardiac and extracardiac pathophysiologic abnormalities, and diverse phenotypic presentations. Since HFpEF is a heterogeneous disease with different phenotypes, individualized treatment is required. HFpEF with type 2 diabetes mellitus (T2DM) represents a specific phenotype of HFpEF, with about 45%-50% of HFpEF patients suffering from T2DM. Systemic inflammation associated with dysregulated glucose metabolism is a critical pathological mechanism of HFpEF with T2DM, which is intimately related to the expansion and dysfunction (inflammation and hypermetabolic activity) of epicardial adipose tissue (EAT). EAT is well established as a very active endocrine organ that can regulate the pathophysiological processes of HFpEF with T2DM through the paracrine and endocrine mechanisms. Therefore, suppressing abnormal EAT expansion may be a promising therapeutic strategy for HFpEF with T2DM. Although there is no treatment specifically for EAT, lifestyle management, bariatric surgery, and some pharmaceutical interventions (anti-cytokine drugs, statins, proprotein convertase subtilisin/kexin type 9 inhibitors, metformin, glucagon-like peptide-1 receptor agonists, and especially sodium-glucose cotransporter-2 inhibitors) have been shown to attenuate the inflammatory response or expansion of EAT. Importantly, these treatments may be beneficial in improving the clinical symptoms or prognosis of patients with HFpEF. Accordingly, well-designed randomized controlled trials are needed to validate the efficacy of current therapies. In addition, more novel and effective therapies targeting EAT are needed in the future.

**Key Words:** Epicardial adipose tissue; Heart failure with preserved ejection fraction; Type 2 diabetes mellitus; Inflammation; Anti-hyperglycemic drugs; Sodium-glucose cotransporter-2 inhibitors

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Shi YJ, Dong GJ, Guo M. Targeting epicardial adipose tissue: A potential therapeutic strategy for heart failure with preserved ejection fraction with type 2 diabetes mellitus. *World J Diabetes* 2023; 14(6): 724-740

**URL**: https://www.wjgnet.com/1948-9358/full/v14/i6/724.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v14.i6.724

**Core Tip:** Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome requiring individualized treatment depending on phenotypic differences. HFpEF with type 2 diabetes mellitus is strongly associated with the expansion, inflammation, and hypermetabolic activity of epicardial adipose tissue (EAT). Thus, targeting EAT may be a promising therapeutic strategy for HFpEF with type 2 diabetes mellitus. Lifestyle management, bariatric surgery, and certain drugs may suppress the accumulation of EAT and improve the clinical symptoms and prognosis of HFpEF. More studies are required to validate the efficacy of current treatments and to develop new effective therapies.

**INTRODUCTION**

Heart failure with preserved ejection fraction (HFpEF), a systemic and heterogeneous syndrome, is characterized by various comorbidities (mainly diabetes mellitus, hypertension, and metabolic syndrome), multiple cardiac and extracardiac pathophysiologic abnormalities, and diverse phenotypic presentations[1]. HFpEF is a growing public health challenge, which currently accounts for approximately half of HF cases, and its prevalence continues to rise due to an aging population and the increasing burden of comorbidities[2]. Additionally, HFpEF is associated with poor prognosis, with a 5-year mortality rate of up to 75%[3]. Standardized and effective interventions are lacking due to the complex pathophysiological underpinnings and clinical heterogeneity of HFpEF[4]. It may, however, be beneficial to halt disease progression and thus improve prognosis by providing individualized treatment based on phenotypic differences[4].

Type 2 diabetes mellitus (T2DM) is a substantial risk factor for the emergence and progression of HFpEF, and approximately 45%-50% of HFpEF cases suffer from T2DM, a specific phenotype of HFpEF[5,6]. Systemic inflammation related to glucose metabolism disorders is accepted as a critical pathological mechanism of HFpEF with T2DM, which is responsible for the expansion and dysfunction (inflammation and hypermetabolic activity) of epicardial adipose tissue (EAT)[7]. EAT, a metabolically active visceral fat depot, can regulate the pathophysiological processes of HFpEF with T2DM through the paracrine and endocrine mechanisms[8]. Thus, inhibiting the accumulation of EAT may be a promising therapeutic strategy for HFpEF with T2DM. At present, lifestyle management, bariatric surgery, and some medications may contribute to reducing the inflammation response or accumulation of EAT, despite the fact that there is no available treatment for EAT. Notably, these interventions may attenuate pathological changes and improve the prognosis in patients with HFpEF.

Currently, a comprehensive review is lacking discussing the pathogenesis of EAT-mediated HFpEF with T2DM and therapies to inhibit EAT expansion. In this review, we evaluated the role of EAT in the development of HFpEF with T2DM and discussed current therapies to attenuate EAT expansion as well as future therapeutic perspectives.

**Anatomy, pathology and pathophysiology of EAT**

***Anatomy of EAT***

EAT represents the local visceral fat depot of the heart, located between the myocardium and the visceral pericardium[9] (Figure 1). Under healthy circumstances, EAT accounts for approximately 20% of the total heart weight and covers 80% of the cardiac surface[10,11]. In adults, EAT typically surrounds the coronary arteries and their major epicardial branches, mainly concentrated in the interventricular and atrioventricular grooves, with lesser amounts covering the atria, the free wall of the right ventricle, and the apex[9]. Interestingly, EAT is anatomically and functionally contiguous with the myocardium because of the shared microcirculation and the absence of muscle fascia, which may facilitate the local interaction of EAT with the myocardium and coronary arteries through vasocrine or paracrine cross-talk[12]. Microscopically, EAT consists typically of adipocytes specialized in energy storage but also includes inflammatory cells (mainly macrophages and mast cells), immune cells, stromovascular cells, and ganglia in normal adults. In pathological states, however, numerous inflammatory cell aggregates and abnormal expansion of the microvascular network are present in the EAT[13].

***Physiology of EAT***

EAT acts as a shock absorber, protecting coronary arteries from excessive distortion and compression during the contraction of the adjacent myocardium[14]. EAT has a greater capacity to release and uptake free fatty acids (FFA) compared to other visceral fat depots. The myocardium metabolizes FFAs from the coronary arterial blood, which is shared with the contiguous EAT. FFA oxidation is responsible for almost 50%-70% of the energy production in the heart[15]. Accordingly, EAT might serve as a physiological buffer to protect the myocardium from excessive fatty acid levels and as a direct energy source to provide FFA under increased metabolic demand. Moreover, EAT expresses uncoupling protein-1 (UCP1), a thermogenic protein located in the inner membrane of mitochondria. UCP1 uncouples oxidative phosphorylation from ATP synthesis, ultimately dissipating energy as heat[16]. EAT might, therefore, provide direct heat to the myocardium and protect the heart under unfavorable hemodynamic conditions.

***Pathophysiology of EAT***

EAT has been widely established as a remarkably active endocrine organ that secretes various bioactive molecules, such as cytokines, adipokines, and chemokines, that can exert protective or detrimental effects depending on the local microenvironmental situation[17]. EAT can, therefore, locally modulate the adjacent myocardium and coronary arteries through the vasocrine or paracrine secretion of these bioactive molecules[12]. Physiologically, EAT mainly releases anti-inflammatory adipocytokines, such as adiponectin, adrenomedullin, omentin, and interleukin-10 (IL-10), which contribute to cardioprotection and anti-atherosclerosis[14]. In contrast, adipocytes enlarge and produce high quantities of FFAs under pathological conditions, triggering EAT expansion, localized hypoxia, and the infiltration of macrophages, ultimately resulting in a chronic inflammatory response[8]. Subsequently, [numerous](https://www.powerthesaurus.org/numerous/synonyms) proinflammatory adipokines are produced and accumulated, including IL-6, tumor necrosis factor-alpha (TNF-α), monocyte chemotactic protein-1, leptin, resistin, and serglycin, which aggravate local inflammation, thereby affecting the heart and coronary arteries[12].

**Contributions of EAT to HFpEF with T2DM**

***EAT in the pathophysiology of HFpEF with T2DM***

Dysregulated glucose metabolism is a fundamental clinical characteristic of T2DM and is strongly connected with the aberrant accumulation of EAT[18-20]. As reported in Table 1, EAT thickness over the right ventricular free wall, EAT volume, or EAT area were significantly higher in patients with impaired fasting glucose, insulin resistance, or T2DM than in control subjects[21-39]. A meta-analysis of nine studies by Li *et al*[40] confirmed a positive correlation between the presence of T2DM and EAT expansion. Eventually, increased EAT deposition interacts directly with the heart through mechanical and metabolic mechanisms, leading to myocardial fibrosis, cardiomyocyte stiffness, and left ventricular (LV) diastolic dysfunction, which are the essential pathological features of HFpEF (Figure 2).

In terms of machinery, increased EAT occupies a large space in the cardiac fossa and applies a compressive contact force on the heart, resulting in pericardial restrain, increased ventricular filling pressures, and LV diastolic dysfunction. A meta-analysis of 11 studies showed that increasing EAT was independently associated with LV diastolic dysfunction even after adjusting for age, sex, and measures of adiposity[41]. In patients with T2DM, [Christensen](https://pubmed.ncbi.nlm.nih.gov/?term=Christensen+RH&cauthor_id=31050126) *et al*[27] and Song *et al*[42] substantiated the deleterious effect of increased EAT on LV global longitudinal strain and LV diastolic function assessed by peak velocity during early diastole (E) /peak velocity during atrial contraction (A) ratio, early diastolic mitral annular velocity (e’), and E/e’ ratio.

In terms of metabolism, EAT enlargement is linked to the buildup of FFAs and lipid metabolites[43], which induce myocardial lipotoxicity and in turn contribute to excessive oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction, ultimately causing LV diastolic dysfunction[44]. Furthermore, excessive cardiomyocyte lipid deposits may lead to cardiac steatosis, which has been demonstrated to be an early marker of diabetic heart disease and is independently associated with LV diastolic function[45-47]. Simultaneously, hypertrophic adipocytes and activated macrophages exhibit increased production of proinflammatory adipocytokines and chemokines in EAT. These proinflammatory factors cause local inflammation, excessive oxidative stress, microvascular and endothelial dysfunction, and extracellular matrix deposition through vasocrine or paracrine mechanisms, resulting in cardiomyocyte stiffness, myocardial fibrosis, and subsequent LV diastolic dysfunction[8,9].

***Relationship between increased EAT and clinical characteristics of HFpEF***

As shown in Table 2, EAT expansion is closely related to severe pathologic changes, clinical manifestations, and long-term prognosis in individuals with HFpEF[48-55]. According to research by van [Woerden](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=van+Woerden+G&cauthor_id=30070041) *et al*[48] and [Pugliese](https://pubmed.ncbi.nlm.nih.gov/?term=Pugliese+NR&cauthor_id=34427016) *et al*[54], enlarged EAT is linked to increased plasma myocardial injury markers. Wang *et al*[49] found that the EAT volume was positively correlated with elevated inflammatory markers (C-reactive protein), LV hypertrophy (LV mass index), and LV diastolic dysfunction (E/e’ ratio and tricuspid regurgitation velocity). [Venkateshvaran](https://pubmed.ncbi.nlm.nih.gov/?term=Venkateshvaran+A&cauthor_id=36196462) *et al*[50]confirmed that higher EAT was linked not only to LV hypertrophy and diastolic dysfunction but also to endothelial dysfunction. Koepp *et al*[51] showed that thickened EAT was associated with elevated cardiac filling pressures, pulmonary hypertension, and pericardial constraint. Additionally, some studies have confirmed that increased EAT may lead to decreased exercise tolerance or quality of life[50-54]. Importantly, EAT thickening was correlated with a 1.12-fold increased risk of the composite endpoint of death and HF hospitalization after 21 mo of follow-up, according to Pugliese *et al*[54]. After 24 mo of follow-up, van Woerden *et al*[55] confirmed that EAT expansion increased the risk of all-cause mortality, HF hospitalization, and the composite endpoint.

**Current Interventions Targeting EAT and Future Therapeutic Perspectives in HFpEF with T2DM**

EAT plays an important role in the development and progression of HFpEF with T2DM and is strongly associated with an increased risk of adverse outcomes. Therefore, alleviating EAT expansion may be a promising therapeutic strategy. Although no treatment is available specifically for EAT, lifestyle management, bariatric surgery, and medications (Table 3) including anti-hyperlipidemia, anti-cytokines, and anti-hyperglycemia have been demonstrated to reduce the inflammation response or expansion of EAT and appear to be beneficial for HFpEF (Figure 3).

***Non-pharmacological interventions***

In diabetic and obese patients, lifestyle modifications (including a low-calorie diet and exercise training) and bariatric surgery can reduce EAT levels. Twenty severely obese patients were shown to have a 32% reduction in EAT thickness and alleviation in LV hypertrophy and diastolic dysfunction after 6 mo of calorie restriction with moderate exercise[56]. Serrano-Ferrer *et al*[57] confirmed that exercise training significantly reduced EAT thickness and serum TNF-α, increased lipocalin, and improved LV myocardial strain and strain rate. A study by Honkala *et al*[58] reported that 2 wk of continuous exercise training resulted in decreased EAT volume and myocardial triglyceride levels and improved aerobic exercise tolerance and insulin sensitivity in 16 patients with T2DM. A meta-analysis including five studies confirmed that exercise training reduced epicardial fat deposition[59].

Several studies have reported that bariatric surgery substantially reduces the accumulation of EAT in patients[60-64]. Gaborit *et al*[62] found a 27% reduction in EAT volume in obese patients at a 6-mo follow-up after bariatric surgery. In addition, individuals with HFpEF appear to benefit from lifestyle changes and bariatric surgery in terms of improved microvascular and endothelial dysfunction, left ventricular remodeling and diastolic dysfunction, exercise tolerance, and quality of life[65-68]. Thus, lifestyle modification and bariatric surgery may alleviate the abnormal expansion of EAT in HFpEF patients with obesity and T2DM and improve LV diastolic function and clinical symptoms. Nevertheless, further research is required to determine whether it can improve the prognosis of patients.

***Pharmacological interventions***

**Anti-cytokine drugs:** Inflammation is an essential driver of abnormal EAT expansion. Theoretically, anti-cytokine drugs (anti-IL-1 and anti-IL-6, *etc*) can interfere with the pathophysiological process of EAT expansion and may eventually decrease EAT accumulation. Unfortunately, there are no relevant studies to confirm this. Furthermore, anti-cytokine drugs, particularly IL-1 blockade, have shown cardioprotective effects in many cardiovascular diseases[69]. Nevertheless, few clinical studies have examined their effects on HFpEF, and the results are inconsistent. The D-HART trial showed that a 14-d intervention with anakinra, an IL-1 blocker, significantly reduced the systemic inflammatory response and improved aerobic exercise capacity in individuals with HFpEF (*n* = 12)[70]. Contrarily, the D-HART 2 trial found that anakinra intervention for 12 d failed to improve exercise capacity in patients with HFpEF (*n* = 21)[71]. Therefore, whether anti-cytokine drugs reduce EAT deposition has not been confirmed in clinical investigations, and their role in HFpEF with T2DM requires validation in standardized randomized controlled trials.

**Anti-hyperlipidemic drugs:** Statins are 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors that can significantly reduce endogenous cholesterol production by inhibiting the rate-limiting enzyme in cholesterol synthesis[72]. As the anti-inflammatory effects have been established, researchers have begun to explore the role of statins in EAT in the last decade. According to Parisi *et al*[73], statin therapy dramatically decreased EAT thickness and EAT-secreted inflammatory mediators in individuals with aortic stenosis. In patients who successfully underwent percutaneous coronary intervention, [Park](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Park+JH&cauthor_id=21253360) *et al*[74] demonstrated that atorvastatin (20 mg/d) reduced EAT thickness more significantly than simvastatin/ezetimibe (10/10 mg/d). [Soucek](https://pubmed.ncbi.nlm.nih.gov/?term=Soucek+F&cauthor_id=26372211) *et al*[75] confirmed that substantial reductions in EAT were associated with intensive atorvastatin therapy (80 mg/d) in atrial fibrillation patients undergoing pulmonary vein isolation. A study by Alexopoulos *et al*[76] showed that intensive treatment (atorvastatin, 80 mg/d) was more successful in inducing EAT reduction than moderate-intensity treatment (pravastatin, 40 mg/d) in hyperlipidemic post-menopausal women.

Furthermore, proprotein convertase subtilisin/kexin type 9 (PCSK9), part of the EAT secretome, is involved in EAT-induced inflammation[77]. Therefore, PCSK9 inhibitors, a new class of lipid-lowering drugs, may inhibit the abnormal expansion of EAT. A non-randomized cohort of 24 patients reported a 20.39% reduction in EAT thickness after 6 mo of PCSK9 inhibitor treatment (evolocumab or alirocumab)[78]. In recent years, statin therapy has been reported to considerably reduce mortality in patients with HFpEF, possibly associated with a reduction in the inflammatory response or accumulation of EAT[79,80]. Thus, hypolipidemic medicines may attenuate aberrant EAT expansion and be advantageous in diabetic HFpEF, and well-designed randomized controlled trials are still needed to validate this.

**Anti-hyperglycemic drugs:** Metformin, an oral anti-hyperglycemic drug for patients with T2DM, lowers blood glucose levels by decreasing hepatic glucose production (gluconeogenesis) and improves insulin sensitivity by increasing peripheral glucose uptake and utilization[81]. In recent years, several studies have begun to explore its impacts on EAT, as its positive effects on reducing body weight and fat composition have been revealed. Iacobellis *et al*[82] showed that metformin treatment (500-1000 mg, twice daily) for 3-6 mo failed to reduce EAT thickness in patients with T2DM. In contrast, Ziyrek *et al*[83] found a significant reduction of EAT thickness after 3 mo of metformin monotherapy (1000 mg, twice daily) in individuals with T2DM. After increasing the sample size, Iacobellis *et al*[84] also discovered that metformin slightly reduced EAT thickness. Additionally, metformin treatment decreased mortality in HFpEF patients and improved LV hypertrophy and diastolic dysfunction[85,86]. Unfortunately, studies on the effects of metformin on EAT accumulation are scarce and controversial, and future research is needed to generate robust evidence.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor gamma (PPAR- γ) agonists, can enhance insulin sensitivity by activating peroxisome proliferator-activated receptor gamma[87]. As a result, it reduces the secretion of proinflammatory cytokines in the visceral fat depots and thereby can inhibit the abnormal enlargement of EAT[88]. Pioglitazone, a member of TZDs, was shown to significantly reduce EAT inflammatory markers (IL-6, TNF-α, resistin, and matrix metalloproteinase-9) and increase adiponectin in patients with coronary artery disease and metabolic syndrome[89]. According to Moody *et al*[90], pioglitazone treatment was linked to a 9% reduction in EAT area and improvement in LV diastolic function in patients with T2DM, and there was a significant negative correlation between EAT and LV diastolic function. However, TZDs may cause serious cardiovascular adverse effects, especially HF[91,92]. As a result, the clinical use of TZDs in the treatment of HFpEF is limited due to their potential to exacerbate HF.

Dipeptidyl peptidase 4 (DPP-4) inhibitors improve glucose-dependent insulin secretion by increasing bioactive incretins, which inhibit glucagon release and then promote insulin production to decrease blood glucose levels[93]. Only a single-group pre-post study by Lima-Martínez *et al*[94] showed that 26 overweight patients with T2DM had a 15% reduction in EAT thickness after 6 mo of treatment with a combination of metformin and sitagliptin, a DPP-4 inhibitor. Unfortunately, there is a lack of research on regulating EAT using DPP-4 inhibitors alone. Therefore, relevant studies still need to support whether DPP-4 inhibitors can reduce EAT accumulation. In addition, it is controversial whether an increased risk of HF is associated with DPP-4 inhibitors[95].

Glucagon-like peptide-1 receptor agonists (GLP1-RAs) comprise a novel anti-diabetic drug class that maintains glucose homeostasis by stimulating glucose-dependent insulin secretion, suppressing glucagon release, and inhibiting gastric emptying[96]. Previous studies reported the presence of GLP-1R in EAT with mRNA and protein expression, and targeting GLP-1R in EAT can reduce local adipogenesis, enhance fat utilization, and drive [brown fat](https://www.sciencedirect.com/topics/medicine-and-dentistry/brown-adipose-tissue) differentiation[97,98]. According to research by van Eyk *et al*[99] and Bizino *et al*[100], liraglutide reduced visceral or subcutaneous fat but failed to reduce EAT accumulation in T2DM. Five investigations, however, demonstrated that liraglutide[82,101-103], exenatide[102,103], semaglutide[104], and dulaglutide[104] not only significantly decreased EAT deposition but also improved glycolipid metabolism disorders. A meta-analysis performed by Berg *et al*[105] confirmed that GLP1-RAs suppressed the abnormal accumulation of EAT. Moreover, liraglutide treatment has been shown to improve LV stiffness and diastolic dysfunction and reduce mortality in HFpEF patients[106]. As a result, GLP1-RAs can inhibit abnormal EAT expansion and may be beneficial for HFpEF. However, further research on this subject is still necessary due to the small numbers of both studies and subjects.

Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is), the newly developed anti-hyperglycemic agents, bind to the SGLT2 transporter in the proximal tubule of the kidney and then promote the urinary excretion of glucose by preventing the reabsorption of glucose[96]. In recent years, SGLT2-Is have been found to play an essential role in mediating anti-inflammatory effects, and therefore its role in regulating EAT has gained significant attention. In individuals undergoing cardiac surgery, Diaz Díaz-Rodríguez *et al*[107] demonstrated the expression of SGLT2 in EAT and that dapagliflozin promoted the differentiation of EAT cells and decreased the release of proinflammatory chemokines in *in vitro* assays. Multiple clinical studies have demonstrated that SGLT2-Is (empagliflozin[108,109], dapagliflozin[84,110-112], canagliflozin[113], ipragliflozin[114], luseogliflozin[115]) can dramatically decrease EAT deposition, improve glucolipid metabolism, and reduce inflammatory responses. Conversely, only one study by [Gabori](https://pubmed.ncbi.nlm.nih.gov/?term=Gaborit+B&cauthor_id=33648515)t *et al*[116] indicated that empagliflozin failed to reduce EAT volume in patients with T2DM.

A meta-analysis conducted by Masson *et al*[117]confirmed that SGLT2-Is could significantly reduce EAT accumulation and improve glucolipid metabolism. Interestingly, [Requena-Ibáñez](https://pubmed.ncbi.nlm.nih.gov/?term=Requena-Ib%C3%A1%C3%B1ez+JA&cauthor_id=34325888) *et al*[108] reported that empagliflozin could reduce EAT volume in patients with non-diabetic HFrEF. According to [Yagi](https://pubmed.ncbi.nlm.nih.gov/?term=Yagi+S&cauthor_id=29034006) *et al*[113], canagliflozin reduced EAT thickness independent of lowering blood glucose. Thus, SGLT2-Is play an essential role in inhibiting EAT accumulation, possibly independent of glycemic control. Moreover, the current studies confirmed that SGLT2-Is exerts direct pleiotropic effects on the myocardium of HFpEF model animals through multiple mechanisms, such as reducing inflammation, suppressing oxidative stress, and improving cardiac structural and functional dysfunction (myocardial hypertrophy, stiffness fibrosis, and LV diastolic dysfunction)[118-121]. Clinically, SGLT2-Is (empagliflozin and dapagliflozin) have been confirmed to improve exercise tolerance[122] and quality of life in HFpEF patients[123,124] and lower the risk of cardiovascular death or HF hospitalization[125-127]. Consequently, SGLT2-Is exhibit significant prevention of abnormal EAT expansion and positive therapeutic effects in HFpEF, which warrants further clinical validation.

**Summary and Future Perspectives**

T2DM can be one of the essential drivers of the occurrence and development of HFpEF and is associated with a worse prognosis of HFpEF. Systemic inflammation associated with glucose metabolism disorders is a crucial pathological mechanism for HFpEF with T2DM, which is associated with the expansion and dysfunction of EAT. EAT is a facilitator of the pathophysiological process of HFpEF, which may promote inflammation, oxidative stress, myocardial steatosis, and myocardial fibrosis *via* vasocrine or paracrine mechanisms, ultimately contributing to LV remodeling and diastolic dysfunction. Accordingly, inhibition of the expansion of EAT may be an attractive therapeutic intervention for HFpEF with T2DM.

Currently, lifestyle management, bariatric surgery, and certain medications related to anti-cytokines, anti-hyperlipidemia, and anti-hyperglycemia can help to alleviate the inflammation and or accumulation of EAT and reduce clinical symptoms or improve long-term prognosis in patients with HFpEF. Nevertheless, the specific mechanisms by which these drugs inhibit EAT expansion remain to be further explored, and clinical studies on their use in HFpEF with T2DM are lacking. As a result, relevant foundational research and well-designed randomized controlled trials are needed to elucidate the pharmacological mechanisms and efficacy of current interventions. Another critical aspect is to develop new methods to suppress the inflammation or expansion of EAT. Concomitantly, it is essential to thoroughly investigate the mechanisms of abnormal accumulation of EAT so that more novel and effective therapies targeting EAT will become available.

**CONCLUSION**

In the development of HFpEF with T2DM, the expansion and dysfunction of EAT exert an essential role. Through vasocrine or paracrine pathways, abnormal EAT accumulation may lead to inflammation, oxidative stress, myocardial steatosis, and myocardial fibrosis, resulting in LV remodeling and diastolic dysfunction, which are essential features of HFpEF. Therefore, targeting EAT may be a prospective therapeutic intervention for HFpEF with T2DM. At present, lifestyle management, bariatric surgery, and pharmaceutical interventions may help alleviate the expansion of EAT and improve the clinical manifestations or prognoses of HFpEF patients. Nonetheless, well-designed randomized controlled studies are required to confirm the efficacy of existing treatments. Moreover, it is hoped that more novel and effective therapies targeting EAT will become available in the future.

**REFERENCES**

1 **Pfeffer MA**, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. *Circ Res* 2019; **124**: 1598-1617 [PMID: 31120821 DOI: 10.1161/CIRCRESAHA.119.313572]

2 **Dunlay SM**, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2017; **14**: 591-602 [PMID: 28492288 DOI: 10.1038/nrcardio.2017.65]

3 **Shah KS**, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. *J Am Coll Cardiol* 2017; **70**: 2476-2486 [PMID: 29141781 DOI: 10.1016/j.jacc.2017.08.074]

4 **Omote K**, Verbrugge FH, Borlaug BA. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. *Annu Rev Med* 2022; **73**: 321-337 [PMID: 34379445 DOI: 10.1146/annurev-med-042220-022745]

5 **Shah SJ**, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. *Circulation* 2016; **134**: 73-90 [PMID: 27358439 DOI: 10.1161/CIRCULATIONAHA.116.021884]

6 **Anker SD**, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Seronde MF, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. *Eur J Heart Fail* 2020; **22**: 2383-2392 [PMID: 33251670 DOI: 10.1002/ejhf.2064]

7 **Packer M**. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. *Cardiovasc Diabetol* 2019; **18**: 121 [PMID: 31551089 DOI: 10.1186/s12933-019-0927-9]

8 **Anthony SR**, Guarnieri AR, Gozdiff A, Helsley RN, Phillip Owens A, Tranter M. Mechanisms linking adipose tissue inflammation to cardiac hypertrophy and fibrosis. *Clin Sci (Lond)* 2019; **133**: 2329-2344 [PMID: 31777927 DOI: 10.1042/CS20190578]

9 **Iacobellis G**. Epicardial adipose tissue in contemporary cardiology. *Nat Rev Cardiol* 2022; **19**: 593-606 [PMID: 35296869 DOI: 10.1038/s41569-022-00679-9]

10 **Corradi D**, Maestri R, Callegari S, Pastori P, Goldoni M, Luong TV, Bordi C. The ventricular epicardial fat is related to the myocardial mass in normal, ischemic and hypertrophic hearts. *Cardiovasc Pathol* 2004; **13**: 313-316 [PMID: 15556777 DOI: 10.1016/j.carpath.2004.08.005]

11 **Shirani J**, Berezowski K, Roberts WC. Quantitative measurement of normal and excessive (cor adiposum) subepicardial adipose tissue, its clinical significance, and its effect on electrocardiographic QRS voltage. *Am J Cardiol* 1995; **76**: 414-418 [PMID: 7639175 DOI: 10.1016/s0002-9149(99)80116-7]

12 **Couselo-Seijas M**, Rodríguez-Mañero M, González-Juanatey JR, Eiras S. Updates on epicardial adipose tissue mechanisms on atrial fibrillation. *Obes Rev* 2021; **22**: e13277 [PMID: 34002458 DOI: 10.1111/obr.13277]

13 **Iacobellis G**, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. *Trends Endocrinol Metab* 2011; **22**: 450-457 [PMID: 21852149 DOI: 10.1016/j.tem.2011.07.003]

14 **Rabkin SW**. Epicardial fat: properties, function and relationship to obesity. *Obes Rev* 2007; **8**: 253-261 [PMID: 17444966 DOI: 10.1111/j.1467-789X.2006.00293.x]

15 **Marchington JM**, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. *Int J Obes* 1990; **14**: 1013-1022 [PMID: 2086494]

16 **Sacks HS**, Fain JN, Bahouth SW, Ojha S, Frontini A, Budge H, Cinti S, Symonds ME. Adult epicardial fat exhibits beige features. *J Clin Endocrinol Metab* 2013; **98**: E1448-E1455 [PMID: 23824424 DOI: 10.1210/jc.2013-1265]

17 **Gaborit B**, Sengenes C, Ancel P, Jacquier A, Dutour A. Role of Epicardial Adipose Tissue in Health and Disease: A Matter of Fat? *Compr Physiol* 2017; **7**: 1051-1082 [PMID: 28640452 DOI: 10.1002/cphy.c160034]

18 **Smith U**, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. *J Intern Med* 2016; **280**: 465-475 [PMID: 27699898 DOI: 10.1111/joim.12540]

19 **Iacobellis G**, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. *J Clin Endocrinol Metab* 2005; **90**: 6300-6302 [PMID: 16091479 DOI: 10.1210/jc.2005-1087]

20 **Burgeiro A**, Fuhrmann A, Cherian S, Espinoza D, Jarak I, Carvalho RA, Loureiro M, Patrício M, Antunes M, Carvalho E. Glucose uptake and lipid metabolism are impaired in epicardial adipose tissue from heart failure patients with or without diabetes. *Am J Physiol Endocrinol Metab* 2016; **310**: E550-E564 [PMID: 26814014 DOI: 10.1152/ajpendo.00384.2015]

21 **Baloglu I**, Turkmen K, Selcuk NY, Tonbul HZ, Ozcicek A, Hamur H, Iyısoy S, Akbas EM. The Relationship Between Visceral Adiposity Index and Epicardial Adipose Tissue in Patients with Type 2 Diabetes Mellitus. *Exp Clin Endocrinol Diabetes* 2021; **129**: 390-395 [PMID: 31060096 DOI: 10.1055/a-0892-4290]

22 **Akbas EM**, Hamur H, Demirtas L, Bakirci EM, Ozcicek A, Ozcicek F, Kuyrukluyildiz U, Turkmen K. Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr* 2014; **6**: 55 [PMID: 24822086 DOI: 10.1186/1758-5996-6-55]

23 **Chen X**, Wu W, Wang L, Shi Y, Shen F, Gu X, Jia Z. Association Between 25-Hydroxyvitamin D and Epicardial Adipose Tissue in Chinese Non-Obese Patients with Type 2 Diabetes. *Med Sci Monit* 2017; **23**: 4304-4311 [PMID: 28877159 DOI: 10.12659/msm.904755]

24 **Philouze C**, Obert P, Nottin S, Benamor A, Barthez O, Aboukhoudir F. Dobutamine Stress Echocardiography Unmasks Early Left Ventricular Dysfunction in Asymptomatic Patients with Uncomplicated Type 2 Diabetes: A Comprehensive Two-Dimensional Speckle-Tracking Imaging Study. *J Am Soc Echocardiogr* 2018; **31**: 587-597 [PMID: 29526563 DOI: 10.1016/j.echo.2017.12.006]

25 **Cetin M**, Cakici M, Polat M, Suner A, Zencir C, Ardic I. Relation of epicardial fat thickness with carotid intima-media thickness in patients with type 2 diabetes mellitus. *Int J Endocrinol* 2013; **2013**: 769175 [PMID: 23762053 DOI: 10.1155/2013/769175]

26 **Yafei S**, Elsewy F, Youssef E, Ayman M, Elshafei M, Abayazeed R. Echocardiographic association of epicardial fat with carotid intima-media thickness in patients with type 2 diabetes. *Diab Vasc Dis Res* 2019; **16**: 378-384 [PMID: 31271311 DOI: 10.1177/1479164119827602]

27 **Christensen RH**, Hansen CS, von Scholten BJ, Jensen MT, Pedersen BK, Schnohr P, Vilsbøll T, Rossing P, Jørgensen PG. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. *Diabetes Obes Metab* 2019; **21**: 2006-2011 [PMID: 31050126 DOI: 10.1111/dom.13758]

28 **Wang Z**, Zhang Y, Liu W, Su B. Evaluation of Epicardial Adipose Tissue in Patients of Type 2 Diabetes Mellitus by Echocardiography and its Correlation with Intimal Medial Thickness of Carotid Artery. *Exp Clin Endocrinol Diabetes* 2017; **125**: 598-602 [PMID: 28494499 DOI: 10.1055/s-0042-114035]

29 **Altin C**, Sade LE, Gezmis E, Yilmaz M, Ozen N, Muderrisoglu H. Assessment of epicardial adipose tissue and carotid/femoral intima media thickness in insulin resistance. *J Cardiol* 2017; **69**: 843-850 [PMID: 27613385 DOI: 10.1016/j.jjcc.2016.08.006]

30 **Iacobellis G**, Barbaro G, Gerstein HC. Relationship of epicardial fat thickness and fasting glucose. *Int J Cardiol* 2008; **128**: 424-426 [PMID: 18375002 DOI: 10.1016/j.ijcard.2007.12.072]

31 **Wang CP**, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, Lu LF, Chung FM, Shin SJ, Lee YJ. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. *Clin Endocrinol (Oxf)* 2009; **70**: 876-882 [PMID: 18778397 DOI: 10.1111/j.1365-2265.2008.03411.x]

32 **Akyürek Ö**, Efe D, Kaya Z. Thoracic periaortic adipose tissue in relation to cardiovascular risk in type 2 diabetes mellitus. *Wien Klin Wochenschr* 2014; **126**: 767-773 [PMID: 25336181 DOI: 10.1007/s00508-014-0611-8]

33 **Gullaksen S**, Funck KL, Laugesen E, Hansen TK, Dey D, Poulsen PL. Volumes of coronary plaque disease in relation to body mass index, waist circumference, truncal fat mass and epicardial adipose tissue in patients with type 2 diabetes mellitus and controls. *Diab Vasc Dis Res* 2019; **16**: 328-336 [PMID: 30714400 DOI: 10.1177/1479164119825761]

34 **Groves EM**, Erande AS, Le C, Salcedo J, Hoang KC, Kumar S, Mohar DS, Saremi F, Im J, Agrawal Y, Nadeswaran P, Naderi N, Malik S. Comparison of epicardial adipose tissue volume and coronary artery disease severity in asymptomatic adults with versus without diabetes mellitus. *Am J Cardiol* 2014; **114**: 686-691 [PMID: 25037677 DOI: 10.1016/j.amjcard.2014.05.057]

35 **Versteylen MO**, Takx RA, Joosen IA, Nelemans PJ, Das M, Crijns HJ, Hofstra L, Leiner T. Epicardial adipose tissue volume as a predictor for coronary artery disease in diabetic, impaired fasting glucose, and non-diabetic patients presenting with chest pain. *Eur Heart J Cardiovasc Imaging* 2012; **13**: 517-523 [PMID: 22312037 DOI: 10.1093/ehjci/jes024]

36 **Huang S**, Li Y, Jiang L, Ren Y, Wang J, Shi K, Yan WF, Qian WL, Yang ZG. Impact of Type 2 Diabetes Mellitus on Epicardial Adipose Tissue and Myocardial Microcirculation by MRI in Postmenopausal Women. *J Magn Reson Imaging* 2022; **56**: 1404-1413 [PMID: 35179821 DOI: 10.1002/jmri.28121]

37 **Evin M**, Broadhouse KM, Callaghan FM, McGrath RT, Glastras S, Kozor R, Hocking SL, Lamy J, Redheuil A, Kachenoura N, Fulcher GR, Figtree GA, Grieve SM. Impact of obesity and epicardial fat on early left atrial dysfunction assessed by cardiac MRI strain analysis. *Cardiovasc Diabetol* 2016; **15**: 164 [PMID: 28007022 DOI: 10.1186/s12933-016-0481-7]

38 **Al-Talabany S**, Mordi I, Graeme Houston J, Colhoun HM, Weir-McCall JR, Matthew SZ, Looker HC, Levin D, Belch JJF, Dove F, Khan F, Lang CC. Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. *BMC Cardiovasc Disord* 2018; **18**: 31 [PMID: 29433433 DOI: 10.1186/s12872-018-0770-z]

39 **Rado SD**, Lorbeer R, Gatidis S, Machann J, Storz C, Nikolaou K, Rathmann W, Hoffmann U, Peters A, Bamberg F, Schlett CL. MRI-based assessment and characterization of epicardial and paracardial fat depots in the context of impaired glucose metabolism and subclinical left-ventricular alterations. *Br J Radiol* 2019; **92**: 20180562 [PMID: 30633543 DOI: 10.1259/bjr.20180562]

40 **Li Y**, Liu B, Li Y, Jing X, Deng S, Yan Y, She Q. Epicardial fat tissue in patients with diabetes mellitus: a systematic review and meta-analysis. *Cardiovasc Diabetol*2019; **18**: 3 [PMID: 30630489 DOI: 10.1186/s12933-019-0807-3]

41 **Nerlekar N**, Muthalaly RG, Wong N, Thakur U, Wong DTL, Brown AJ, Marwick TH. Association of Volumetric Epicardial Adipose Tissue Quantification and Cardiac Structure and Function. *J Am Heart Assoc* 2018; **7**: e009975 [PMID: 30571602 DOI: 10.1161/JAHA.118.009975]

42 **Song XT**, Wang SK, Zhang PY, Fan L, Rui YF. Association between epicardial adipose tissue and left ventricular function in type 2 diabetes mellitus: Assessment using two-dimensional speckle tracking echocardiography. *J Diabetes Complications* 2022; **36**: 108167 [PMID: 35272930 DOI: 10.1016/j.jdiacomp.2022.108167]

43 **Kankaanpää M**, Lehto HR, Pärkkä JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. *J Clin Endocrinol Metab* 2006; **91**: 4689-4695 [PMID: 16926257 DOI: 10.1210/jc.2006-0584]

44 **Leggat J**, Bidault G, Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? *Clin Sci (Lond)* 2021; **135**: 2265-2283 [PMID: 34643676 DOI: 10.1042/CS20210127]

45 **Rijzewijk LJ**, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. *J Am Coll Cardiol* 2008; **52**: 1793-1799 [PMID: 19022158 DOI: 10.1016/j.jacc.2008.07.062]

46 **Korosoglou G**, Humpert PM, Ahrens J, Oikonomou D, Osman NF, Gitsioudis G, Buss SJ, Steen H, Schnackenburg B, Bierhaus A, Nawroth PP, Katus HA. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. *J Magn Reson Imaging* 2012; **35**: 804-811 [PMID: 22068959 DOI: 10.1002/jmri.22879]

47 **McGavock JM**, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. *Circulation* 2007; **116**: 1170-1175 [PMID: 17698735 DOI: 10.1161/CIRCULATIONAHA.106.645614]

48 **van Woerden G**, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. *Eur J Heart Fail* 2018; **20**: 1559-1566 [PMID: 30070041 DOI: 10.1002/ejhf.1283]

49 **Wang X**, Butcher SC, Kuneman JH, Lustosa RP, Fortuni F, Ajmone Marsan N, Knuuti J, Bax JJ, Delgado V. The Quantity of Epicardial Adipose Tissue in Patients Having Ablation for Atrial Fibrillation With and Without Heart Failure. *Am J Cardiol* 2022; **172**: 54-61 [PMID: 35317933 DOI: 10.1016/j.amjcard.2022.02.021]

50 **Venkateshvaran A**, Faxen UL, Hage C, Michaëlsson E, Svedlund S, Saraste A, Beussink-Nelson L, Fermer ML, Gan LM, Tromp J, Lam CSP, Shah SJ, Lund LH. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study. *Eur J Heart Fail* 2022; **24**: 2251-2260 [PMID: 36196462 DOI: 10.1002/ejhf.2709]

51 **Koepp KE**, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail* 2020; **8**: 657-666 [PMID: 32653449 DOI: 10.1016/j.jchf.2020.04.016]

52 **Haykowsky MJ**, Nicklas BJ, Brubaker PH, Hundley WG, Brinkley TE, Upadhya B, Becton JT, Nelson MD, Chen H, Kitzman DW. Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail* 2018; **6**: 640-649 [PMID: 30007558 DOI: 10.1016/j.jchf.2018.06.002]

53 **Gorter TM**, van Woerden G, Rienstra M, Dickinson MG, Hummel YM, Voors AA, Hoendermis ES, van Veldhuisen DJ. Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail* 2020; **8**: 667-676 [PMID: 32653444 DOI: 10.1016/j.jchf.2020.06.003]

54 **Pugliese NR**, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, Mengozzi A, Virdis A, Nesti L, Taddei S, Flammer A, Borlaug BA, Ruschitzka F, Masi S. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. *Eur J Heart Fail* 2021; **23**: 1858-1871 [PMID: 34427016 DOI: 10.1002/ejhf.2337]

55 **van Woerden G**, van Veldhuisen DJ, Manintveld OC, van Empel VPM, Willems TP, de Boer RA, Rienstra M, Westenbrink BD, Gorter TM. Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. *Circ Heart Fail* 2022; **15**: e009238 [PMID: 34935412 DOI: 10.1161/CIRCHEARTFAILURE.121.009238]

56 **Iacobellis G**, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. *Obesity (Silver Spring)* 2008; **16**: 1693-1697 [PMID: 18451775 DOI: 10.1038/oby.2008.251]

57 **Serrano-Ferrer J**, Crendal E, Walther G, Vinet A, Dutheil F, Naughton G, Lesourd B, Chapier R, Courteix D, Obert P. Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial. *Metabolism* 2016; **65**: 1350-1360 [PMID: 27506742 DOI: 10.1016/j.metabol.2016.05.006]

58 **Honkala SM**, Motiani KK, Eskelinen JJ, Savolainen A, Saunavaara V, Virtanen KA, Löyttyniemi E, Kapanen J, Knuuti J, Kalliokoski KK, Hannukainen JC. Exercise Training Reduces Intrathoracic Fat Regardless of Defective Glucose Tolerance. *Med Sci Sports Exerc* 2017; **49**: 1313-1322 [PMID: 28628064 DOI: 10.1249/MSS.0000000000001232]

59 **Launbo N**, Zobel EH, von Scholten BJ, Faerch K, Jørgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: A systematic review and meta-analysis. *Obes Rev* 2021; **22**: e13136 [PMID: 32896056 DOI: 10.1111/obr.13136]

60 **Hunt SC**, Davidson LE, Adams TD, Ranson L, McKinlay RD, Simper SC, Litwin SE. Associations of Visceral, Subcutaneous, Epicardial, and Liver Fat with Metabolic Disorders up to 14 Years After Weight Loss Surgery. *Metab Syndr Relat Disord* 2021; **19**: 83-92 [PMID: 33136533 DOI: 10.1089/met.2020.0008]

61 **Wu FZ**, Huang YL, Wu CC, Wang YC, Pan HJ, Huang CK, Yeh LR, Wu MT. Differential Effects of Bariatric Surgery Versus Exercise on Excessive Visceral Fat Deposits. *Medicine (Baltimore)* 2016; **95**: e2616 [PMID: 26844473 DOI: 10.1097/MD.0000000000002616]

62 **Gaborit B**, Jacquier A, Kober F, Abdesselam I, Cuisset T, Boullu-Ciocca S, Emungania O, Alessi MC, Clément K, Bernard M, Dutour A. Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. *J Am Coll Cardiol* 2012; **60**: 1381-1389 [PMID: 22939560 DOI: 10.1016/j.jacc.2012.06.016]

63 **Salman AA**, Salman MA, Soliman A, Youssef A, Labib S, Helmy MY, Marie MA, Shawkat M, Mostafa A, Tourky MS, Sarhan MD, Qassem MG, Shaaban HE, Omar MG, Abouelregal TE. Changes of epicardial fat thickness after laparoscopic sleeve gastrectomy: a prospective study. *Ann Med* 2021; **53**: 523-530 [PMID: 34008443 DOI: 10.1080/07853890.2021.1903072]

64 **Willens HJ**, Byers P, Chirinos JA, Labrador E, Hare JM, de Marchena E. Effects of weight loss after bariatric surgery on epicardial fat measured using echocardiography. *Am J Cardiol* 2007; **99**: 1242-1245 [PMID: 17478151 DOI: 10.1016/j.amjcard.2006.12.042]

65 **Kitzman DW**, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, Eggebeen J, Nicklas BJ. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. *JAMA* 2016; **315**: 36-46 [PMID: 26746456 DOI: 10.1001/jama.2015.17346]

66 **Pandey A**, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B, Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. *Circ Heart Fail* 2015; **8**: 33-40 [PMID: 25399909 DOI: 10.1161/CIRCHEARTFAILURE.114.001615]

67 **Angadi SS**, Mookadam F, Lee CD, Tucker WJ, Haykowsky MJ, Gaesser GA. High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. *J Appl Physiol (1985)* 2015; **119**: 753-758 [PMID: 25190739 DOI: 10.1152/japplphysiol.00518.2014]

68 **Aggarwal R**, Harling L, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. The Effects of Bariatric Surgery on Cardiac Structure and Function: a Systematic Review of Cardiac Imaging Outcomes. *Obes Surg* 2016; **26**: 1030-1040 [PMID: 26328532 DOI: 10.1007/s11695-015-1866-5]

69 **Szekely Y**, Arbel Y. A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today? *Cardiol Ther* 2018; **7**: 25-44 [PMID: 29417406 DOI: 10.1007/s40119-018-0104-3]

70 **Van Tassell BW**, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). *Am J Cardiol* 2014; **113**: 321-327 [PMID: 24262762 DOI: 10.1016/j.amjcard.2013.08.047]

71 **Van Tassell BW**, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, Dixon D, Biondi-Zoccai G, Arena R, Abbate A. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail* 2018; **11**: e005036 [PMID: 30354558 DOI: 10.1161/CIRCHEARTFAILURE.118.005036]

72 **Istvan ES**, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. *Science* 2001; **292**: 1160-1164 [PMID: 11349148 DOI: 10.1126/science.1059344]

73 **Parisi V**, Petraglia L, D'Esposito V, Cabaro S, Rengo G, Caruso A, Grimaldi MG, Baldascino F, De Bellis A, Vitale D, Formisano R, Ferro A, Paolillo S, Davin L, Lancellotti P, Formisano P, Perrone Filardi P, Ferrara N, Leosco D. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. *Int J Cardiol* 2019; **274**: 326-330 [PMID: 30454723 DOI: 10.1016/j.ijcard.2018.06.106]

74 **Park JH**, Park YS, Kim YJ, Lee IS, Kim JH, Lee JH, Choi SW, Jeong JO, Seong IW. Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. *J Cardiovasc Ultrasound* 2010; **18**: 121-126 [PMID: 21253360 DOI: 10.4250/jcu.2010.18.4.121]

75 **Soucek F**, Covassin N, Singh P, Ruzek L, Kara T, Suleiman M, Lerman A, Koestler C, Friedman PA, Lopez-Jimenez F, Somers VK. Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation. *Am J Cardiol* 2015; **116**: 1443-1446 [PMID: 26372211 DOI: 10.1016/j.amjcard.2015.07.067]

76 **Alexopoulos N**, Melek BH, Arepalli CD, Hartlage GR, Chen Z, Kim S, Stillman AE, Raggi P. Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). *J Am Coll Cardiol* 2013; **61**: 1956-1961 [PMID: 23500254 DOI: 10.1016/j.jacc.2012.12.051]

77 **Dozio E**, Ruscica M, Vianello E, Macchi C, Sitzia C, Schmitz G, Tacchini L, Corsi Romanelli MM. PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation. *Mediators Inflamm* 2020; **2020**: 1348913 [PMID: 32565719 DOI: 10.1155/2020/1348913]

78 **Rivas Galvez RE,** Morales Portano JD, Trujillo Cortes R, Gomez Alvarez EB, Sanchez Cubias SM, Zelaya SM. Reduction of epicardial adipose tissue thickness with PCSK9 inhibitors. *Eur Heart J* 2020; **41**: ehaa946.3008 [DOI: 10.1093/ehjci/ehaa946.3008]

79 **Alehagen U**, Benson L, Edner M, Dahlström U, Lund LH. Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of ≥50. *Circ Heart Fail* 2015; **8**: 862-870 [PMID: 26243795 DOI: 10.1161/CIRCHEARTFAILURE.115.002143]

80 **Fukuta H**, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. *Int J Cardiol* 2016; **214**: 301-306 [PMID: 27082778 DOI: 10.1016/j.ijcard.2016.03.186]

81 **LaMoia TE**, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. *Endocr Rev* 2021; **42**: 77-96 [PMID: 32897388 DOI: 10.1210/endrev/bnaa023]

82 **Iacobellis G**, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. *Obesity (Silver Spring)* 2017; **25**: 311-316 [PMID: 28124506 DOI: 10.1002/oby.21718]

83 **Ziyrek M**, Kahraman S, Ozdemir E, Dogan A. Metformin monotherapy significantly decreases epicardial adipose tissue thickness in newly diagnosed type 2 diabetes patients. *Rev Port Cardiol (Engl Ed)* 2019; **38**: 419-423 [PMID: 31324408 DOI: 10.1016/j.repc.2018.08.010]

84 **Iacobellis G**, Gra-Menendez S. Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. *Obesity (Silver Spring)* 2020; **28**: 1068-1074 [PMID: 32352644 DOI: 10.1002/oby.22798]

85 **Gu J**, Yin ZF, Zhang JF, Wang CQ. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension. *Int J Cardiol* 2020; **306**: 140-145 [PMID: 31711850 DOI: 10.1016/j.ijcard.2019.11.087]

86 **Halabi A**, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. *Cardiovasc Diabetol* 2020; **19**: 124 [PMID: 32758236 DOI: 10.1186/s12933-020-01100-w]

87 **Cariou B**, Charbonnel B, Staels B. Thiazolidinediones and PPARγ agonists: time for a reassessment. *Trends Endocrinol Metab* 2012; **23**: 205-215 [PMID: 22513163 DOI: 10.1016/j.tem.2012.03.001]

88 **Lefterova MI**, Haakonsson AK, Lazar MA, Mandrup S. PPARγ and the global map of adipogenesis and beyond. *Trends Endocrinol Metab* 2014; **25**: 293-302 [PMID: 24793638 DOI: 10.1016/j.tem.2014.04.001]

89 **Grosso AF**, de Oliveira SF, Higuchi Mde L, Favarato D, Dallan LA, da Luz PL. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. *Diabetol Metab Syndr* 2014; **6**: 47 [PMID: 24684779 DOI: 10.1186/1758-5996-6-47]

90 **Moody AJ**, Molina-Wilkins M, Clarke GD, Merovci A, Solis-Herrera C, Cersosimo E, Chilton RJ, Iozzo P, Gastaldelli A, Abdul-Ghani M, DeFronzo RA. Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. *Diabetes Obes Metab* 2023; **25**: 426-434 [PMID: 36204991 DOI: 10.1111/dom.14885]

91 **Lago RM**, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet* 2007; **370**: 1129-1136 [PMID: 17905165 DOI: 10.1016/S0140-6736(07)61514-1]

92 **Nassif M**, Kosiborod M. Effect of glucose-lowering therapies on heart failure. *Nat Rev Cardiol* 2018; **15**: 282-291 [PMID: 29368701 DOI: 10.1038/nrcardio.2017.211]

93 **Deacon CF**. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* 2020; **16**: 642-653 [PMID: 32929230 DOI: 10.1038/s41574-020-0399-8]

94 **Lima-Martínez MM**, Paoli M, Rodney M, Balladares N, Contreras M, D'Marco L, Iacobellis G. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. *Endocrine* 2016; **51**: 448-455 [PMID: 26233684 DOI: 10.1007/s12020-015-0710-y]

95 **Li L**, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, Wong E, Busse JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. *BMJ* 2016; **352**: i610 [PMID: 26888822 DOI: 10.1136/bmj.i610]

96 **Palmer SC**, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ* 2021; **372**: m4573 [PMID: 33441402 DOI: 10.1136/bmj.m4573]

97 **Dozio E**, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G, Corsi Romanelli MM. Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: A target to modulate cardiovascular risk? *Int J Cardiol* 2019; **292**: 218-224 [PMID: 31023563 DOI: 10.1016/j.ijcard.2019.04.039]

98 **Iacobellis G**, Camarena V, Sant DW, Wang G. Human Epicardial Fat Expresses Glucagon-Like Peptide 1 and 2 Receptors Genes. *Horm Metab Res* 2017; **49**: 625-630 [PMID: 28514806 DOI: 10.1055/s-0043-109563]

99 **van Eyk HJ**, Paiman EHM, Bizino MB, de Heer P, Geelhoed-Duijvestijn PH, Kharagjitsingh AV, Smit JWA, Lamb HJ, Rensen PCN, Jazet IM. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. *Cardiovasc Diabetol*2019; **18**: 87 [PMID: 31288820 DOI: 10.1186/s12933-019-0890-5]

100 **Bizino MB**, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. *Diabetologia* 2020; **63**: 65-74 [PMID: 31690988 DOI: 10.1007/s00125-019-05021-6]

101 **Zhao N**, Wang X, Wang Y, Yao J, Shi C, Du J, Bai R. The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes. *J Diabetes Res* 2021; **2021**: 5578216 [PMID: 34825006 DOI: 10.1155/2021/5578216]

102 **Dutour A**, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. *Diabetes Obes Metab* 2016; **18**: 882-891 [PMID: 27106272 DOI: 10.1111/dom.12680]

103 **Morano S**, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. *Acta Diabetol* 2015; **52**: 727-732 [PMID: 25577244 DOI: 10.1007/s00592-014-0710-z]

104 **Iacobellis G**, Villasante Fricke AC. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity. *J Endocr Soc* 2020; **4**: bvz042 [PMID: 32190806 DOI: 10.1210/jendso/bvz042]

105 **Berg G**, Barchuk M, Lobo M, Nogueira JP. Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. *Diabetes Metab Syndr* 2022; **16**: 102562 [PMID: 35816950 DOI: 10.1016/j.dsx.2022.102562]

106 **Nguyen TD**, Shingu Y, Amorim PA, Schenkl C, Schwarzer M, Doenst T. GLP-1 Improves Diastolic Function and Survival in Heart Failure with Preserved Ejection Fraction. *J Cardiovasc Transl Res* 2018; **11**: 259-267 [PMID: 29464655 DOI: 10.1007/s12265-018-9795-z]

107 **Díaz-Rodríguez E**, Agra RM, Fernández ÁL, Adrio B, García-Caballero T, González-Juanatey JR, Eiras S. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. *Cardiovasc Res* 2018; **114**: 336-346 [PMID: 29016744 DOI: 10.1093/cvr/cvx186]

108 **Requena-Ibáñez JA**, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, Atallah-Lajam F, Giannarelli C, Macaluso F, Lala A, Sanz J, Fuster V, Badimon JJ. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: From the EMPA-TROPISM Study. *JACC Heart Fail* 2021; **9**: 578-589 [PMID: 34325888 DOI: 10.1016/j.jchf.2021.04.014]

109 **Ardahanlı İ,** Aslan R, Çelik M, Akgün O, Akyüz O. Effects of Empagliflozin on Carotid Intima-Media Thickness and Epicardial Fat Tissue Volume in Patients with Type-2 Diabetes Mellitus. *Lokman Hekim Health Sci* 2021; **1**: 74-80 [DOI: 10.14744/lhhs.2021.80001]

110 **Sato T**, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. *Cardiovasc Diabetol* 2018; **17**: 6 [PMID: 29301516 DOI: 10.1186/s12933-017-0658-8]

111 **Sato T**, Aizawa Y, Yuasa S, Fujita S, Ikeda Y, Okabe M. The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume and P-Wave Indices: An Ad-hoc Analysis of The Previous Randomized Clinical Trial. *J Atheroscler Thromb* 2020; **27**: 1348-1358 [PMID: 32115470 DOI: 10.5551/jat.48009]

112 **Braha A**, Albai A, Timar B, Cipu D, Vasiluță L, Potre O, Timar R. Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes. *Medicina (Kaunas)* 2021; **58** [PMID: 35056329 DOI: 10.3390/medicina58010021]

113 **Yagi S**, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D, Salim HM, Maimaituxun G, Nishio S, Takagawa Y, Hama S, Matsuura T, Yamaguchi K, Tobiume T, Soeki T, Wakatsuki T, Aihara KI, Akaike M, Shimabukuro M, Sata M. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr* 2017; **9**: 78 [PMID: 29034006 DOI: 10.1186/s13098-017-0275-4]

114 **Fukuda T**, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study. *Diabetes Ther* 2017; **8**: 851-861 [PMID: 28616806 DOI: 10.1007/s13300-017-0279-y]

115 **Bouchi R**, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. *Cardiovasc Diabetol* 2017; **16**: 32 [PMID: 28253918 DOI: 10.1186/s12933-017-0516-8]

116 **Gaborit B**, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, Lasbleiz A, Peiretti F, Bornet CE, Lefur Y, Pini L, Rapacchi S, Bernard M, Resseguier N, Darmon P, Kober F, Dutour A. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. *Cardiovasc Diabetol* 2021; **20**: 57 [PMID: 33648515 DOI: 10.1186/s12933-021-01237-2]

117 **Masson W**, Lavalle-Cobo A, Nogueira JP. Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis. *Cells* 2021; **10** [PMID: 34440918 DOI: 10.3390/cells10082150]

118 **Kolijn D**, Pabel S, Tian Y, Lódi M, Herwig M, Carrizzo A, Zhazykbayeva S, Kovács Á, Fülöp GÁ, Falcão-Pires I, Reusch PH, Linthout SV, Papp Z, van Heerebeek L, Vecchione C, Maier LS, Ciccarelli M, Tschöpe C, Mügge A, Bagi Z, Sossalla S, Hamdani N. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. *Cardiovasc Res* 2021; **117**: 495-507 [PMID: 32396609 DOI: 10.1093/cvr/cvaa123]

119 **Pabel S**, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tschöpe C, Streckfuss-Bömeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S. Empagliflozin directly improves diastolic function in human heart failure. *Eur J Heart Fail*2018; **20**: 1690-1700 [PMID: 30328645 DOI: 10.1002/ejhf.1328]

120 **Cappetta D**, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Miccichè A, Dell'Aversana C, D'Amario D, Cianflone E, Scavone C, Santini L, Palandri C, Naviglio S, Crea F, Rota M, Altucci L, Rossi F, Capuano A, Urbanek K, Berrino L. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. *Pharmacol Res* 2020; **157**: 104781 [PMID: 32360273 DOI: 10.1016/j.phrs.2020.104781]

121 **He L**, Ma S, Zuo Q, Zhang G, Wang Z, Zhang T, Zhai J, Guo Y. An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats. *Front Pharmacol* 2022; **13**: 856386 [PMID: 35370704 DOI: 10.3389/fphar.2022.856386]

122 **Nassif ME**, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F, Khariton Y, Malik AO, Khumri T, Umpierrez G, Lamba S, Sharma K, Khan SS, Chandra L, Gordon RA, Ryan JJ, Chaudhry SP, Joseph SM, Chow CH, Kanwar MK, Pursley M, Siraj ES, Lewis GD, Clemson BS, Fong M, Kosiborod MN. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. *Nat Med* 2021; **27**: 1954-1960 [PMID: 34711976 DOI: 10.1038/s41591-021-01536-x]

123 **Butler J**, Filippatos G, Jamal Siddiqi T, Brueckmann M, Böhm M, Chopra VK, Pedro Ferreira J, Januzzi JL, Kaul S, Piña IL, Ponikowski P, Shah SJ, Senni M, Vedin O, Verma S, Peil B, Pocock SJ, Zannad F, Packer M, Anker SD. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. *Circulation* 2022; **145**: 184-193 [PMID: 34779658 DOI: 10.1161/CIRCULATIONAHA.121.057812]

124 **Spertus JA**, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN, Januzzi JL. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. *Nat Med* 2022; **28**: 809-813 [PMID: 35228753 DOI: 10.1038/s41591-022-01703-8]

125 **Huynh K**. Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved. *Nat Rev Cardiol* 2021; **18**: 737 [PMID: 34526679 DOI: 10.1038/s41569-021-00627-z]

126 **Solomon SD**, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *N Engl J Med* 2022; **387**: 1089-1098 [PMID: 36027570 DOI: 10.1056/NEJMoa2206286]

127 **Zhao L**, Guo W, Huang W, Wang L, Huang S. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. *Diabetes Res Clin Pract* 2022; **187**: 109871 [PMID: 35413392 DOI: 10.1016/j.diabres.2022.109871]

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest associated with the senior author or coauthor who contributed their efforts to this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 28, 2022

**First decision:** February 8, 2023

**Article in press:** April 24, 2023

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Eiras S, Spain; Papazafiropoulou A, Greece; Xu L, China **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:** Cai YX


**Figure Legends**

****

**Figure 1 Anatomical location of epicardial adipose tissue.** Epicardial adipose tissue (EAT) is situated between the myocardium and the visceral pericardium. In normal adults, EAT usually accompanies the coronary arteries and their major epicardial branches, mainly concentrated in the interventricular and atrioventricular grooves, with lesser amounts covering the atria, the free wall of the right ventricle, and the apex.

****

**Figure 2 Epicardial adipose tissue in the pathophysiology of heart failure with preserved ejection fraction with type 2 diabetes mellitus.** Dysregulated glucose metabolism is intimately related to the expansion of epicardial adipose tissue (EAT). Increased EAT deposition interacts directly with the heart through mechanical and metabolic mechanisms. Mechanically, EAT expansion may directly contribute to pericardial restrain, resulting in left ventricular (LV) diastolic dysfunction. Metabolically, EAT enlargement is linked to the buildup of free fatty acids, which may induce myocardial lipotoxicity and cardiac steatosis. Simultaneously, hypertrophic adipocytes and activated macrophages secrete numerous proinflammatory adipocytokines and chemokines in EAT. Subsequent local inflammation, excessive oxidative stress, microvascular and endothelial dysfunction, and myocardial stiffness and fibrosis ultimately lead to LV remodeling and diastolic dysfunction.

****

**Figure 3 Current interventions targeting epicardial adipose tissue and possible mechanisms.** Current interventions targeting epicardial adipose tissue (EAT) reported in the literature include non-pharmacological interventions (lifestyle management and bariatric surgery) and pharmacological interventions related to anti-cytokines, anti-hyperlipidemia, and anti-hyperglycemia. By increasing fat oxidation or sensitivity to insulin and inhibiting inflammation or hypermetabolic activity, these interventions may prevent abnormal expansion and inflammation of EAT. EAT: Epicardial adipose tissue; DPP-4: Dipeptidyl peptidase 4; GLP1-RAs: Glucagon-like peptide-1 receptor agonists; PCSK9: Proprotein convertase subtilisin/kexin type 9; SGLT2-Is: Sodium-glucose cotransporter 2 inhibitors; TZDs: Thiazolidinediones.

**Table 1 Epicardial adipose tissue expansion in patients with glucose metabolism disorders**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Participants, *n*** | **Amount** **of EAT in the observation** **group** | **Amount of EAT in the control group** | ***P* value** |
| EAT thickness (mm) measured by echocardiography thickness on the right ventricular free wall | | | | |
| [Baloglu](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Baloglu+I&cauthor_id=31060096) *et al*[21],2019 | T2DM patients: 128; healthy controls: 32 | 3.53 ± 0.79 | 4.64 ± 1.39 | < 0.001 |
| [Akbas](https://pubmed.ncbi.nlm.nih.gov/?term=Akbas+EM&cauthor_id=24822086) *et al*[22],2014 | T2DM patients: 156; healthy controls: 50 | 4.66 ± 1.50 | 3.91 ± 1.60 | 0.005 |
| [Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+X&cauthor_id=28877159) *et al*[23],2017 | T2DM patients: 167; healthy controls: 82 | 4.00 (3.00-5.00) | 2.00 (1.00-3.00) | < 0.001 |
| [Philouze](https://pubmed.ncbi.nlm.nih.gov/?term=Philouze+C&cauthor_id=29526563) *et al*[24],2017 | T2DM patients: 44; healthy controls: 35 | 6.40 ± 1.70 | 3.30 ± 1.10 | < 0.001 |
| [Cetin](https://pubmed.ncbi.nlm.nih.gov/?term=Cetin+M&cauthor_id=23762053) *et al*[25],2013 | T2DM patients: 139; age- and sex-matched controls: 40 | 6.00 ± 1.50 | 4.42 ± 1.00 | < 0.001 |
| [Yafei](https://pubmed.ncbi.nlm.nih.gov/?term=Yafei+S&cauthor_id=31271311) *et al*[26],2019 | T2DM patients: 76; age- and sex-matched controls: 30 | 6.23 ± 1.27 | 4.60 ± 1.03 | < 0.001 |
| [Christensen](https://pubmed.ncbi.nlm.nih.gov/?term=Christensen+RH&cauthor_id=31050126) *et al*[27],2019 | T2DM patients: 770; age- and sex-matched controls: 234 | 4.60 ± 1.80 | 3.40 ± 1.20 | < 0.0001 |
| [Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+Z&cauthor_id=28494499) *et al*[28],2017 | T2DM with duration ≤ 10 yr: 35; T2DM with duration > 10 yr: 33 | 4.47 ± 1.90 | 5.45 ± 1.40 | < 0.05 |
| [Altin](https://pubmed.ncbi.nlm.nih.gov/?term=Altin+C&cauthor_id=27613385) *et al*[29],2016 | Patients with IR: 113; age- and sex-matched controls: 112 | 7.34 ± 1.96 | 5.22 ± 1.75 | < 0.001 |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=18375002) *et al*[30],2008 | Patients with IFG: 65; non-diabetic controls: 50 | Males: 8.00 ± 3.00 | 6.00 ± 2.00 | < 0.001 |
|  |  | Females: 7.10 ± 4.00 | 5.80 ± 3.00 |  |
| EAT volume (cm3) measured by computed tomography | | | | |
| Wang *et al*[31],2008 | T2DM patients: 49; non-diabetic controls: 78 | 166.1 ± 60.6 | 123.4 ± 41.8 | < 0.0001 |
| [Akyürek](https://pubmed.ncbi.nlm.nih.gov/?term=Aky%C3%BCrek+%C3%96&cauthor_id=25336181) *et al*[32],2014 | T2DM patients: 93; non-diabetic controls: 85 | 40.1 ± 23.9 | 16.9 ± 7.7 | < 0.001 |
| [Gullaksen](https://pubmed.ncbi.nlm.nih.gov/?term=Gullaksen+S&cauthor_id=30714400) *et al*[33],2019 | T2DM patients: 44; non-diabetic controls: 59 | 119.0 ± 49.0 | 86.0 ± 40.0 | < 0.001 |
| [Groves](https://pubmed.ncbi.nlm.nih.gov/?term=Groves+EM&cauthor_id=25037677) *et al*[34],2014 | T2DM patients: 92; non-diabetic controls: 59 | 118.6 ± 43.0 | 70.0 ± 44.0 | < 0.0001 |
| [Versteylen](https://pubmed.ncbi.nlm.nih.gov/?term=Versteylen+MO&cauthor_id=22312037) *et al*[35],2012 | Patients with IFG: 118; non-diabetic controls: 209 | 92.0 ± 39.0 | 75.0 ± 34.0 | < 0.001 |
| EAT volume (cm3) or area (cm2) measured by cardiac magnetic resonance | | | | |
| [Huang](https://pubmed.ncbi.nlm.nih.gov/?term=Huang+S&cauthor_id=35179821) *et al*[36],2022 | T2DM with duration ≤ 5 yr: 56; T2DM with duration > 5 yr: 57 | 48.4 ± 13.4 cm3 | 58.4 ± 17.3 cm3 | < 0.001 |
| [Evin](https://pubmed.ncbi.nlm.nih.gov/?term=Evin+M&cauthor_id=28007022) *et al*[37],2016 | T2DM patients: 20; healthy controls: 19 | 135.0 ± 31.0 cm3 | 90.0 ± 30.0 cm3 | < 0.001 |
| [Al-Talabany](https://pubmed.ncbi.nlm.nih.gov/?term=Al-Talabany+S&cauthor_id=29433433) *et al*[38],2018 | T2DM patients: 54; non-diabetic controls: 29 | 13.5 ± 3.5 cm2 | 11.8 ± 4.1 cm2 | < 0.05 |
| [Rado](https://pubmed.ncbi.nlm.nih.gov/?term=Rado+SD&cauthor_id=30633543) *et al*[39],2019 | Prediabetes patients: 100; healthy controls: 200 | 9.2 cm2 | 7.7 cm2 | < 0.001 |

EAT: Epicardial adipose tissue; IFG: Impaired fasting glucose; IR: Insulin resistance; T2DM: Type 2 diabetes mellitus.

**Table 2** **Relationship between increased epicardial adipose tissue and clinical characteristics of heart failure with preserved ejection fraction**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Pa****rticipants, *n*** | **Imaging method** | **Relationship between increased EAT and clinical characteristics of HFpEF** | | |
| **Pathological changes** | **Clinical manifestations** | **Prognosis** |
| van [Woerden](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=van+Woerden+G&cauthor_id=30070041) *et al*[48], 2018 | 64 HF patients with LVEF > 40% | CMR | Myocardial injury: increased creatine kinase-MB and TnT | Decreased quality of life (KCCQ score) |  |
| [Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+X&cauthor_id=35317933) *et al*[49], 2022 | 53 HF patients with LVEF > 50% | CMR | Inflammation: increased CRP; LV hypertrophy: increased LVmass index; LV diastolic dysfunction: increased E/e' and tricuspid regurgitation velocity |  |  |
| [Venkateshvaran](https://pubmed.ncbi.nlm.nih.gov/?term=Venkateshvaran+A&cauthor_id=36196462) *et al*[50], 2022 | 182 HF patients with LVEF > 50% | Echo | Inflammation; endothelial dysfunction; LV hypertrophy: increased LV septal wall thickness; LV diastolic dysfunction: increased E peak deceleration time | Decreased quality of life (KCCQ score) |  |
| [Koepp](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Koepp+KE&cauthor_id=32653449) *et al*[51], 2020 | 169 HF patients with LVEF > 50% | Echo | Increased cardiac filling pressures, pulmonary hypertension, and pericardial restraint | Decreased exercise capacity (VO2, AVO2 diff) |  |
| [Haykowsky](https://pubmed.ncbi.nlm.nih.gov/?term=Haykowsky+MJ&cauthor_id=30007558) *et al*[52], 2018 | 100 HF patients with LVEF > 50% | CMR |  | Decreased exercise capacity (VO2, 6-min walk test, leg power) |  |
| [Gorter](https://pubmed.ncbi.nlm.nih.gov/?term=Gorter+TM&cauthor_id=32653444) *et al*[53], 2020 | 75 HF patients with LVEF > 45% | Echo |  | Decreased exercise capacity (VO2) |  |
| [Pugliese](https://pubmed.ncbi.nlm.nih.gov/?term=Pugliese+NR&cauthor_id=34427016) *et al*[54], 2021 | 188 HF patients with LVEF > 50% | Echo | Myocardial injury: increased TnT; inflammation: increased CRP | Decreased exercise capacity (peak VO2 and AVO2 diff) | Increased risk of the composite endpoint of HF hospitalization and cardiovascular deaths |
| van [Woerden](https://pubmed.ncbi.nlm.nih.gov/?term=van+Woerden+G&cauthor_id=34935412) *et al*[55], 2022 | 105 HF patients with LVEF > 40% | CMR |  |  | Increased risk of HF hospitalization, all-cause death, and the composite endpoint |

AVO2 diff: Non-invasive arterial-venous oxygen content difference; CMR: Cardiac magnetic resonance; CRP: C-reactive protein; EAT: Epicardial adipose tissue; Echo: Echocardiography; E/e': Peak velocity during early diastole/early diastolic mitral annular velocity; HF: Heart failure; HFpEF: Heart failure with preserved ejection fraction; KCCQ: Kansas City cardiomyopathy questionnaire; LV: Left ventricular; LVEF: Left ventricular ejection fraction; MB: Myocardial band; TnT: Troponin T; VO2: Peak oxygen consumption.

**Table 3 Pharmacological interventions targeting epicardial adipose tissue**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Imaging method** | **Participants, *n*** | **Intervention method and duration** | **Change of EAT** | **Other** **findings** |
| [Park](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Park+JH&cauthor_id=21253360) *et al*[74], 2010 | Echo | 145 coronary artery stenosis patients | Atorvastatin: *n* = 82, 20 mg/d; simvastatin: *n* = 63, 10 mg/d; for 6-8 mo | Atorvastatin decreased EAT thickness (0.47 ± 0.65 mm) more than simvastatin (EAT 0.12 ± 0.52 mm, *P* = 0.001) | Decreased TC, TG, and LDL-C |
| [Soucek](https://pubmed.ncbi.nlm.nih.gov/?term=Soucek+F&cauthor_id=26372211) *et al*[75], 2015 | CT | 38 atrial fibrillation patients | Atorvastatin: 80 mg/d, for 3 mo | EAT volume decreased from 86.9 (64.1-124.8) mL to 92.3 (62.0- 133.3) mL (*P* < 0.05) | Decreased CRP, TC, and LDL-C |
| [Alexopoulos](https://pubmed.ncbi.nlm.nih.gov/?term=Alexopoulos+N&cauthor_id=23500254) *et al*[76], 2013 | CT | 420 hyperlipidemic post-menopausal women | Atorvastatin: *n* = 194, 80 mg/d; pravastatin: *n* = 226, 40 mg/d; for 12 mo | Atorvastatin decreased EAT volume (3.38%) more than pravastatin (0.83%, *P* = 0.025) | Decreased TC, TG, and LDL-C |
| Rivas Galvez *et al*[78], 2020 | Echo | 41 patients treated with PCSK9 inhibitors | Evolocumab: *n* = 16; alirocumab: *n* = 8; twice in 6 mo | EAT thickness decreased by 20.39% (*P* = 0.0001). | Decreased BMI, TC, and LDL-C |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=32352644) *et al*[82], 2017 | Echo | 41 patients T2DM | Metformin: 500 mg-1000 mg, twice daily, for 6 mo | EAT thickness changed from 7.4 ± 1.6 mm to 7.5 ± 1.5 mm and 6.9 ± 1.3 mm at 3 and 6 mo, respectively | Decreased BMI |
| [Ziyrek](https://pubmed.ncbi.nlm.nih.gov/?term=Ziyrek+M&cauthor_id=31324408) *et al*[83], 2019 | Echo | 40 T2DM patients | Metformin: 1000 mg, twice daily, for 3 mo | EAT thickness decreased from 5.07 ± 1.33 mm to 4.76 ± 1.32 mm (*P* < 0.001) |  |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=32352644) *et al*[84], 2020 | Echo | 51 T2DM patients | Metformin: 500 mg-1000 mg, twice daily, for 6 mo | EAT thickness decreased from 8.0 ± 2.5 mm to 7.4 ± 2.5 mm and 7.5 ± 2.4 mm at 3 and 6 mo, respectively (compared with baseline *P* < 0.016) |  |
| [Moody](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Moody+AJ&cauthor_id=36204991) *et al*[90], 2014 | CMR | 12 T2DM patients | Pioglitazone: 15 mg/d, for 2 wk, then increase to 45 mg/d, for 22 wk | EAT area decreased from 15.3 ± 3.9 cm2 to 14.0 ± 3.9 cm2 (*P* = 0.03) | Decreased paracardial adipose tissue; improved left ventricular diastolic function |
| [Lima-Martínez](https://pubmed.ncbi.nlm.nih.gov/?term=Lima-Mart%C3%ADnez+MM&cauthor_id=26233684) *et al*[94], 2015 | Echo | 26 T2DM patients | Combination of sitagliptin (50 mg) and metformin (1000 mg), twice daily, for 24 wk | EAT thickness reduction of 15% (*P* = 0.001) |  |
| van [Eyk](https://pubmed.ncbi.nlm.nih.gov/?term=van+Eyk+HJ&cauthor_id=31288820) *et al*[99], 2019 | CMR | 22 T2DM patients | Liraglutide: 0.6 mg/d gradually increased to 1.8 mg/d in 2 wk, for 26 wk | EAT area reduction of 0 ± 2 cm2 | Decreased visceral fat volume |
| [Bizino](https://pubmed.ncbi.nlm.nih.gov/?term=Bizino+MB&cauthor_id=31690988) *et al*[100], 2020 | CMR | 23 T2DM patients | Liraglutide: 0.6 mg/d gradually increased to 1.8 mg/d in 2 wk, 26 wk | EAT area reduction of 1.1 ± 6.0 cm2 | Decreased body weight and subcutaneous fat |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=28124506) *et al*[82], 2017 | Echo | 54 T2DM patients | Combination of liraglutide (increased to 1.8 mg/once daily) and metformin (1000 mg, twice daily), for 12 wk | EAT thickness reduction of 29% and 36% at 3 and 6 mo, respectively | Decreased BMI and HbA1c |
| [Zhao](https://pubmed.ncbi.nlm.nih.gov/?size=200&term=Zhao+N&cauthor_id=34825006) *et al*[101], 2021 | Echo | 21 T2DM patients | Liraglutide: 0.6 mg/d gradually increased to 1.2 mg/d in 3-5 d, for 3 mo | EAT decreased from 5.00 (5.0-7.0) mm to 3.95 ± 1.43 mm (*P* < 0.001) | Decreased weight, HbA1c, TC, TG, and LDL-C |
| [Dutour](https://pubmed.ncbi.nlm.nih.gov/?term=Dutour+A&cauthor_id=27106272) *et al*[102], 2016 | CMR | 22 T2DM patients | Exenatide: 5 mg twice daily, for 4 wk, then increase to 10 mg twice daily, for 22 wk | EAT volume reduction of 8.8 ± 2.1% | Decreased weight, HbA1c, and hepatic triglyceride content |
| [Morano](https://pubmed.ncbi.nlm.nih.gov/?term=Morano+S&cauthor_id=25577244) *et al*[103], 2015 | Echo | 25 T2DM patients | Combination of exenatide (5 mg twice daily, for 1 mo, and then increase to 10 mg twice daily, for 2 mo) and liraglutide (1.2 mg/d), for 3 mo | EAT thickness decreased from 9.4 ± 1.6 mm to 8.0 ± 1.9 mm (*P* = 0.003) | Decreased MRI; improved renal resistive index |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=32190806) *et al*[104], 2020 | Echo | 6 T2DM patients | Semaglutide: *n* = 30, 1 mg weekly; dulaglutide: *n* = 30, 1.5 mg weekly; for 12 wk | EAT thickness reduction of 20% in both semaglutide and dulaglutide groups | Decreased BMI and HbA1c |
| [Requena-Ibáñez](https://pubmed.ncbi.nlm.nih.gov/?term=Requena-Ib%C3%A1%C3%B1ez+JA&cauthor_id=34325888) *et al*[108], 2021 | CMR | 84 non-diabetic patients with HFrEF | Empagliflozin: 10 mg/d, for 6 mo | EAT volume reduction of 5.14 mL, *P* < 0.05 | Decreasing subcutaneous fat and matrix volume |
| Ardahanlı *et al*[109], 2021 | Echo | 37 T2DM patients | Empagliflozin: 10 mg/d, for 6 mo | EAT thickness decreased from 7.6 ± 1.7 mm to 6.7 ± 1.3 mm (*P* < 0.001) | Decreased BMI, waist circumference, HbA1c, uric acid, systolic and diastolic blood pressure, and carotid intima-media thickness |
| [Iacobellis](https://pubmed.ncbi.nlm.nih.gov/?term=Iacobellis+G&cauthor_id=32352644) *et al*[84], 2020 | Echo | 51 T2DM patients | Combination of dapagliflozin (5 to 10 mg/d) and metformin (500 to 1000 mg, twice daily), for 24 mo | EAT thickness decreased by 15% from baseline to 12 wk and 20% after 24 wk (compared with baseline *P* < 0.01) | Decreased weight and HbA1c |
| [Sato](https://pubmed.ncbi.nlm.nih.gov/?term=Sato+T&cauthor_id=29301516) *et al*[110], 2018 | CT | 20 T2DM patients | Dapagliflozin: 10 mg/d, for 6 mo | EAT volume reduction of 16.4 ± 8.3 mL (*P* < 0.05) | Decreased HbA1c, TNF-α, TG, insulin resistance, and left atrial dimension |
| [Sato](https://pubmed.ncbi.nlm.nih.gov/?term=Sato+T&cauthor_id=32115470) *et al*[111], 2020 | CT | 18 T2DM patients with coronary artery disease | Dapagliflozin: 5 mg/d, for 6 mo | EAT volume reduction of 15.2 ± 12.8 mL (*P* < 0.05) | Decreased HbA1c, TNF-α, and insulin resistance |
| [Braha](https://pubmed.ncbi.nlm.nih.gov/?term=Braha%20A%5BAuthor%5D) *et al*[112], 2021 | CT | 52 T2DM patients | Dapagliflozin: 10 mg/d, for 6 mo | EAT volume reduction of 17.1% (*P* < 0.001) | Decreased BMI, triglyceride glucose index, and HbA1c |
| [Yagi](https://pubmed.ncbi.nlm.nih.gov/?term=Yagi+S&cauthor_id=29034006) *et al*[113], 2017 | Echo | 13 T2DM patients | Canagliflozin: 100 mg/d, for 6 mo | EAT thickness decreased from 9.3 ± 2.5 to 8.1 ± 2.3 mm (*P* < 0.01) and to 7.3 ± 2.0 mm (*P* < 0.001) at 3 mo and 6 mo, respectively | Decreased BMI |
| [Fukuda](https://pubmed.ncbi.nlm.nih.gov/?term=Fukuda%20T%5BAuthor%5D) *et al*[114], 2017 | CMR | 9 T2DM patients | Ipragliflozin: 50 mg/d, 12 wk | EAT volume decreased from 102 (79-126) mL to 89 (66-109) mL (*P* = 0.008) | Decreased weight, BMI, HbA1c, TG, leptin, fasting plasma glucose, and insulin resistance |
| [Bouchi](https://pubmed.ncbi.nlm.nih.gov/?term=Bouchi+R&cauthor_id=28253918) *et al*[115], 2017 | CMR | 19 T2DM patients | Luseogliflozin: 2.5-5.0 mg/d for 12 wk | EAT volume decreased from 117 (96-136) mL to 111 (88-134) mL (*P* = 0.048) | Decreased weight, BMI, systolic and diastolic blood pressure, HbA1c, fasting plasma glucose, insulin resistance, and CRP |
| [Gabori](https://pubmed.ncbi.nlm.nih.gov/?term=Gaborit+B&cauthor_id=33648515)t *et al*[116], 2021 | CMR | 26 T2DM patients | Empagliflozin: 10 mg/d, 12 wk | EAT volume decreased from 108.5 ± 31.8 mL to 106.9 ± 31.8 mL (*P* = 0.09) | Decreased BMI, TG, HbA1c, fasting blood glucose, liver fat content, and visceral fat volume |

BMI: Body mass index; CMR: Cardiovascular magnetic resonance; CRP: C-reactive protein; CT: Computed tomography; EAT: Epicardial adipose tissue; Echo: Echocardiography; HbA1c: Glycosylated hemoglobin; HFrEF: Heart failure with reduced ejection fraction; LDL-C: Low-density lipoprotein cholesterol; MRI: Magnetic resonance imaging; PCSK9: Proprotein convertase subtilisin/kexin type 9; T2DM: Type 2 diabetes mellitus; TC: Total cholesterol; TG: Triglycerides; TNF-α: Tumor necrosis factor-α.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**